Assessing dengue vaccination impact: Model challenges and future directions.

[1]  E. Massad,et al.  Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine , 2016, Expert review of vaccines.

[2]  Katya Galactionova,et al.  Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models , 2016, The Lancet.

[3]  B. Guy,et al.  Dengue vaccine: hypotheses to understand CYD-TDV-induced protection , 2015, Nature Reviews Microbiology.

[4]  Anavaj Sakuntabhai,et al.  Asymptomatic humans transmit dengue virus to mosquitoes , 2015, Proceedings of the National Academy of Sciences.

[5]  Nicholas Jackson,et al.  Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. , 2015, The New England journal of medicine.

[6]  Duane J. Gubler,et al.  A Critical Assessment of Vector Control for Dengue Prevention , 2015, PLoS neglected tropical diseases.

[7]  G. Carrasquilla,et al.  Efficacy of a tetravalent dengue vaccine in children in Latin America. , 2015, The New England journal of medicine.

[8]  P. Pitisuttithum,et al.  Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial , 2014, The Lancet.

[9]  K. Fink,et al.  Dengue Serotype Cross-Reactive, Anti-E Protein Antibodies Confound Specific Immune Memory for 1 Year after Infection , 2014, Front. Immunol..

[10]  Kirsten A. Duda,et al.  Global spread of dengue virus types: mapping the 70 year history , 2014, Trends in microbiology.

[11]  L. Meyers,et al.  Probabilistic uncertainty analysis of epidemiological modeling to guide public health intervention policy. , 2014, Epidemics.

[12]  Pejman Rohani,et al.  Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity , 2013, Journal of The Royal Society Interface.

[13]  Radhika Dhingra,et al.  Sensitivity analysis of infectious disease models: methods, advances and their application , 2013, Journal of The Royal Society Interface.

[14]  John S. Brownstein,et al.  The global distribution and burden of dengue , 2013, Nature.

[15]  J. Berkhof,et al.  Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts , 2013, BMC Medicine.

[16]  N. Hens,et al.  Dynamic Epidemiological Models for Dengue Transmission: A Systematic Review of Structural Approaches , 2012, PloS one.

[17]  Mario Recker,et al.  Assessing the Potential of a Candidate Dengue Vaccine with Mathematical Modeling , 2012, PLoS neglected tropical diseases.

[18]  Michael A. Johansson,et al.  Models of the impact of dengue vaccines: a review of current research and potential approaches. , 2011, Vaccine.

[19]  M. Jit,et al.  Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world , 2011, BMC medicine.

[20]  A. Melegaro,et al.  Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools , 2011, BMC medicine.

[21]  R. Hutubessy,et al.  Results from evaluations of models and cost-effectiveness tools to support introduction decisions for new vaccines need critical appraisal , 2011, BMC medicine.

[22]  M. Jit,et al.  Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models , 2011, BMC medicine.

[23]  D. Dassey.  Outbreak , 1995, The Lancet.

[24]  M. Guzmán,et al.  Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981. , 1989, Bulletin of the World Health Organization.

[25]  A. Nisalak,et al.  A prospective study of dengue infections in Bangkok. , 1988, The American journal of tropical medicine and hygiene.

[26]  A. Sabin.  Research on dengue during World War II. , 1952, The American journal of tropical medicine and hygiene.